Tag Archive for: cancer

Pieere Fabre' R&D centre at Oncopole in Toulouse. © Par Don-vip - wikipedia.org

Pierre Fabre Médicament SAS has entered into an Asset Purchase Agreement (APA) over pan-RAF programs developed by Kinnate Biopharma Inc.

Curve Therapeutics' CSO and co-founder Ali Tavassoli. © University of Southampton

Intracellular cancer target screening specialist Curve Therapeutics Ltd has closed a £40.5m financing led by Pfizer Ventures to advance its preclinical pipeline of small cyclic petides.

Chart of the penny stock Vidac Pharma Holdings. © onvista.de

London-based Vidac Pharma Holding plc reported that its Warburg effect blocker VDA-1275 increased efficacy of chemotherapeutics 1000-fold in human organoid cancer models for liver cancer.

© Freenome Inc

Multi-omics liquid biospy specialist Freenome Inc. has baged US$254m in a financing round led by Roche AG to fund early cancer detection in 6,200 patients using its AI-guided cancer detection platform.

Amplys team around CEO Ben Thomas (4th from left). © Amply Discovery Ltd

Belfast-based techbio company AMPLY Discovery Ltd announced today will make use of a £1.4m in grant funding to advance its AI-based drug discovery platform.

Corporate headquarters of Jazz Pharmaceuticals are located in Dublin, Ireland. © Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.

© Giovanni Cancemi - stock.adobe.c

Researchers uncover a potential strategy to target and inhibit the androgen receptor in aggressive prostate cancer by exploiting protein droplets.

ADC in action, illustration by @ImmunoGen Inc.

AbbVie buys ImmunoGen in US$10 billion deal, gains access to ADC for ovarian cancer. The ADC space gets hotter and hotter.

Picture: AAX Biotech

The Swedish start-up AAX Biotech welcomed Maria Lisa Knudsen as its new Managing Director at the end of September.

© catalin - stock.adobe.com

Pierre Fabre Laboratories, a leading French medical and beauty care company and Vernalis (R&D) Ltd, a fully owned subsidiary of HitGen Inc. and a specialist in drug discovery announce a long-term partnership for oncology drug discovery.